Eric Fischer

Eric Fischer, a structural biologist at Dana-Farber Cancer Institute, dives into the innovative world of targeted protein degraders. He shares his early fascination with biology, recounts how thalidomide revealed new drug mechanisms, and contrasts PROTACs with molecular glues. Fischer discusses the importance of industry partnerships for translating academic discoveries into therapies and highlights the exciting potential of degraders in cancer treatment and beyond. Plus, he reflects on the collaborative environment in American research.